Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30
   PubMed Web of Science ®Google Scholar
• Egusquiaguirre SP, Igartua M, Hernandez RM, Pedraz JL. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol 2012;14:83–93
   PubMed Web of Science ®Google Scholar
• Saenz Del Burgo L, Hernandez RM, Orive G, Pedraz JL. Nanotherapeutic approaches for brain cancer management. Nanomed Nanotechnol Biol Med 2014;10:905–19
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010;10:345–52
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95–106
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317–27
   PubMed Web of Science ®Google Scholar
• Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993;14:483–6
   PubMedGoogle Scholar
• Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487–94
   PubMedGoogle Scholar
• Hellstrom I, Hellstrom KE. Tumor immunology: an overview. Ann NY Acad Sci 1993;690:24–33
   PubMed Web of Science ®Google Scholar
• Compte M, Blanco B, Serrano F, et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA × anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007;14:380–8
   PubMed Web of Science ®Google Scholar
• Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 1997;45:131–6
   PubMed Web of Science ®Google Scholar
• Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012;4:182–97
   PubMed Web of Science ®Google Scholar
• Segal DM, Weiner GJ, Weiner LM. Introduction: bispecific antibodies. J Immunol Methods 2001;248:1–6
   PubMed Web of Science ®Google Scholar
• Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? Mabs 2009;1:539–47
   PubMed Web of Science ®Google Scholar
• Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999;11:558–62
   PubMed Web of Science ®Google Scholar
• Tibben JG, Boerman OC, Massuger LF, et al. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Int J Cancer 1996;66:477–83
   PubMed Web of Science ®Google Scholar
• Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 1995;4:453–6
   PubMedGoogle Scholar
• Acarregui A, Murua A, Pedraz JL, et al. A perspective on bioactive cell microencapsulation. BioDrugs 2012;26:283–301
   PubMed Web of Science ®Google Scholar
• Hernandez RM, Orive G, Murua A, Pedraz JL. Microcapsules and microcarriers for in situ cell delivery. Adv Drug Deliv Rev 2010;62:711–30
   PubMed Web of Science ®Google Scholar
• Orive G, Santos E, Pedraz JL, Hernandez RM. Application of cell encapsulation for controlled delivery of biological therapeutics. Adv Drug Deliv Rev 2014;67–68:3–14
   Google Scholar
• Dubrot J, Portero A, Orive G, et al. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. Cancer Immunol Immunother 2010;59:1621–31
   PubMed Web of Science ®Google Scholar
• Compte M, Nunez-Prado N, Sanz L, Alvarez-Vallina L. Immunotherapeutic organoids: a new approach to cancer treatment. Biomatter 2013;3:e23897
   PubMedGoogle Scholar
• Nolan KF, Yun CO, Akamatsu Y, et al. Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999;5:3928–41
   PubMed Web of Science ®Google Scholar
• Blanco B, Holliger P, Vile RG, Alvarez-Vallina L. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immun 2003;171:1070–7
   PubMed Web of Science ®Google Scholar
• Compte M, Cuesta AM, Sanchez-Martin D, et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 2009;27:753–60
   PubMed Web of Science ®Google Scholar
• Alonso-Camino V, Santos-Valle P, Ispizua MC, et al. Engineered human tumor xenografts with functional human vascular networks. Microvasc Res 2011;81:18–25
   PubMed Web of Science ®Google Scholar
• Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993;90:6444–8
   PubMed Web of Science ®Google Scholar
• Chester KA, Begent RH, Robson L, et al. Phage libraries for generation of clinically useful antibodies. Lancet 1994;343:455–6
   PubMed Web of Science ®Google Scholar
• Salmerón A, Sánchez-Madrid F, Ursa MA, et al. A conformational epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies. J Immunol 1991;147:3047–52
   PubMed Web of Science ®Google Scholar
• Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980;210:908–10
   PubMed Web of Science ®Google Scholar
• Thu B, Bruheim P, Espevik T, et al. Alginate polycation microcapsules. I. Interaction between alginate and polycation. Biomaterials 1996;17:1031–40
   PubMed Web of Science ®Google Scholar
• Murua A, de CM, Orive G, et al. In vitro characterization and in vivo functionality of erythropoietin-secreting cells immobilized in alginate-poly-l-lysine-alginate microcapsules. Biomacromolecules 2007;8:3302–7
   PubMed Web of Science ®Google Scholar
• Ponce S, Orive G, Hernandez RM, et al. Chemistry and the biological response against immunoisolating alginate-polycation capsules of different composition. Biomaterials 2006;27:4831–9
   PubMed Web of Science ®Google Scholar
• de Vos P, Wolters GH, van SR. Possible relationship between fibrotic overgrowth of alginate–polylysine–alginate microencapsulated pancreatic islets and the microcapsule integrity. Transplant.Proc 1994;26:782–3
   PubMed Web of Science ®Google Scholar
• Rihova B. Immunocompatibility and biocompatibility of cell delivery systems. Adv Drug Deliv Rev 2000;42:65–80
   PubMed Web of Science ®Google Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118–29
   PubMed Web of Science ®Google Scholar
• Sanz L, Cuesta AM, Compte M, Alvarez-Vallina L. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin 2005;26:641–8
   PubMed Web of Science ®Google Scholar
• Sanchez-Martin D, Sanz L, Alvarez-Vallina L. Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins. Curr Opin Biotechnol 2011;22:924–30
   PubMed Web of Science ®Google Scholar
• Sanz L, Compte M, Guijarro-Munoz I, Alvarez-Vallina L. Non-hematopoietic stem cells as factories for in vivo therapeutic protein production. Gene Ther 2012;19:1–7
   PubMed Web of Science ®Google Scholar
• Sanz L, Blanco B, Alvarez-Vallina L. Antibodies and gene therapy: teaching old ‘magic bullets' new tricks. Trends Immunol 2004;25:85–91
   PubMed Web of Science ®Google Scholar
• Wilson JT, Chaikof EL. Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv Drug Deliv Rev 2008;60:124–45
   PubMed Web of Science ®Google Scholar
• Sugiura S, Oda T, Izumida Y, et al. Size control of calcium alginate beads containing living cells using micro-nozzle array. Biomaterials 2005;26:3327–31
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557–63
   PubMed Web of Science ®Google Scholar
• Sanz L, Santos-Valle P, Alonso-Camino V, et al. Long-term in vivo imaging of human angiogenesis: critical role of bone marrow-derived mesenchymal stem cells for the generation of durable blood vessels. Microvasc Res 2008;75:308–14
   PubMed Web of Science ®Google Scholar
• Murua A, Herran E, Orive G, et al. Design of a composite drug delivery system to prolong functionality of cell-based scaffolds. Int J Pharm 2011;407:142–50
   PubMed Web of Science ®Google Scholar
• Orive G, de CM, Ponce S, et al. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules. Mol Ther 2005;12:283–9
   PubMed Web of Science ®Google Scholar
• Murua A, Orive G, Hernandez RM, Pedraz JL. Cryopreservation based on freezing protocols for the long-term storage of microencapsulated myoblasts. Biomaterials 2009;30:3495–501
   PubMed Web of Science ®Google Scholar
• Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci 2012;37:106–26
   PubMed Web of Science ®Google Scholar
• Santos E, Larzabal L, Calvo A, et al. Inactivation of encapsulated cells and their therapeutic effects by means of TGL triple-fusion reporter/biosafety gene. Biomaterials 2013;34:1442–51
   PubMed Web of Science ®Google Scholar
• Sommer B, Rinsch C, Payen E, et al. Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts. Mol Ther 2002;6:155–61
   PubMed Web of Science ®Google Scholar
• Cirone P, Bourgeois JM, Austin RC, Chang PL. A novel approach to tumor suppression with microencapsulated recombinant cells. Hum Gene Ther 2002;13:1157–66
   PubMed Web of Science ®Google Scholar
• Cirone P, Shen F, Chang PL. A multiprong approach to cancer gene therapy by coencapsulated cells. Cancer Gene Ther 2005;12:369–80
   PubMed Web of Science ®Google Scholar
• Read TA, Sorensen DR, Mahesparan R, et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 2001;19:29–34
   PubMed Web of Science ®Google Scholar
• Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006;12:693–8
   PubMed Web of Science ®Google Scholar
• Sangro B, Melero I, Qian C, Prieto J. Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005;5:573–81
   PubMed Web of Science ®Google Scholar